Jennifer Litton, MD

Jennifer Litton, MD, associate professor in the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses her opinion on the use of PARP inhibitors in the field of breast cancer.

Recent research has led to the availability of numerous drugs for the treatment of HER2+ breast cancer, while PARP inhibitors are only the first targeted therapy for triple-negative breast cancer to meet a primary endpoint. These will be tested in a variety of combinations in the future, Litton predicts.

PARP inhibitors are currently only being used in cases of metastatic breast cancer with a

germline mutation. But, Litton notes, we cannot forget about ER+ breast cancer as well, even though there are only a small percent of these patients with a

Videos

Jennifer Litton, MD, associate professor in the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses her opinion on the use of PARP inhibitors in the field of breast cancer.&nbsp;

Addressing the Role of PARP Inhibitors in Different Breast Cancer Settings

Jennifer Litton, MD, associate professor in the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses the role of biosimilars in the treatment of breast cancer.

The cost of cancer treatments has become one of the biggest concerns to oncologists as they treat their patients, Litton says.

It is not ideal to send a patient into debt while they are being treated, and often times oncologists are making their decisions regarding treatment based off cost. Economic toxicity is a major issue in the field of breast cancer, as well as many other cancers, Litton notes.

Jennifer Litton, MD | Authors

Articles

Addressing the Role of PARP Inhibitors in Different Breast Cancer Settings

Exploring Biosimilars in the Field of Breast Cancer